SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glaxosmithkline Consumer Healthcare is currently trading at Rs. 4305.00, up by 26.00 points or 0.61 % from its previous closing of Rs. 4279.00 on the BSE.

The scrip opened at Rs. 4305.00 and has touched a high and low of Rs. 4319.00 and Rs. 4301.05 respectively. So far 80 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 6020.00 on 31-May-2013 and a 52 week low of Rs. 2900.00 on 09-Oct-2012.

Last one week high and low of the scrip stood at Rs. 4433.90 and Rs. 4250.00 respectively. The current market cap of the company is Rs. 18119.21 crore.

The promoters holding in the company stood at 72.46% while Institutions and Non-Institutions held 12.35% and 15.20% respectively.

GlaxoSmithKline Pharmaceuticals’ (GSK Pharma) sales continue to be affected in the major pockets of the country as its products are not being purchased by stockists and retailers from September 15, 2013.

No reason was immediately attributed for this trend but earlier in August the company had said a number of its products have come under the Drug Price Control Order (DPCO) 2013 which has come into effect in May 2013, resulting in reduction of prices of the company’s drugs.

GlaxoSmithKline Pharmaceuticals is one oldest pharmaceutical company in India. Internationally it has created many brands such as Ribena, Horlicks, Lucozade, Aquafresh, Sensodyne, Panadol, Tums and Zovirax, among others. It employs 5,000 people and has turnover of more than $1 billion in India.

Glaxo.Cons. Health Share Price

9696.40 0.00 (0.00%)
15-Apr-2020 18:01 View Price Chart
Peers
Company Name CMP
Varun Beverages 484.95
Nestle 1410.05
Britannia Inds 5670.35
LT Foods 417.80
Hatsun Agro Product 1009.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×